Raptor rises as RP103 misses Huntington's endpoint
This article was originally published in Scrip
Executive Summary
Raptor Pharmaceutical's RP103 (delayed-release cysteamine) did not meet the primary endpoint in a Phase II/III Huntington's disease clinical trial, but the company's stock still soared 14.9% higher on 20 February.